Manage Your Liver
Q:

I was recently diagnosed with NASH, I was told by my gastroenterologist that there is no available treatment. What can I do?

A:

Currently, there is no approved treatment for NASH. [1] As the underlying cause for the transition from simple fat buildup in the liver to NASH remain unknown, conventional medical therapies for NASH have not yet been proven to be effective. 

The recommendations medical professionals often give to people with NASH are to follow a healthy diet and do exercise. [2] Those who are overweight or obese are advised to lose weight, but this can be difficult and not every individual finds these interventions effective. 

There are things NASH patients can do other than losing weight. Apart from lifestyle changes, NASH patients should also focus on protecting their liver, reducing inflammation in the liver cells and preventing progression of the disease. In the long run, this can help to reduce the risk of cirrhosis and liver cancer.

A clinical study on PubMed suggests that YHK, an alternative therapy from Japan, has an inhibitory effect on the development of NASH; and its anti-inflammatory effect can effectively stop inflammation in the liver. [3] Other research papers also demonstrate that YHK has anti-fibrotic properties which prevent further damage to the liver such as fibrosis or cirrhosis. [4][5]

Stopping the progression of NASH is possible. But it will require putting in great effort to leading a healthy lifestyle and reducing fat and inflammation in the liver with the help of the above mentioned nutraceutical. Avoiding the use of alcohol and unnecessary medications can also decrease the risk of liver damage.

Disclaimer:
  • * All research and clinical data should be used as reference purposes only, results may vary.
Tags:
NASHNonalcoholic SteatohepatitisYHKYHK Therapy
Related Questions
A:
NASH is inflammation in the liver developed from accumulated fat in the organ, also known as fatty liver. NASH damages liver cells and liver function, which results in elevated ALT liver enzyme level.    As there are no approved treatments for NASH, the standard recommendation for patients is to lose weight only. However this doesn’t work for everyone so if you are struggling to find a way to stop NASH, please read on.   Wha
A:
There are between 10 to 15 million patients in the U.S. with NASH, and among these patients, one-fifth to one-fourth are at risk for cirrhosis or chronic liver damage.   The major characteristic of NASH is fat in the liver, along with inflammation and damage. NASH can be severe and can lead to cirrhosis. The number of NASH cirrhosis patients is currently on the rise, and it is predicted (NAFLD & NASH) to be the number 1 cause of liver transplants by 2020. [1] Ther
Hit Questions
A:
Research and developing our products has always been a big part of our work. Kyotsujigyo has worked with a number of well established organisations and universities in the past, including the University of Sao Paulo, GAIA Age-Management Foundation, The University of Western Ontario, University of Virginia, Yanaihara Research Institute,  Harada Hospital (Japan) and others.    In 2016 Kyotsujigyo has corporate with the National Key Research Institute in Hong K
A:
NASH is inflammation in the liver developed from accumulated fat in the organ, also known as fatty liver. NASH damages liver cells and liver function, which results in elevated ALT liver enzyme level.    As there are no approved treatments for NASH, the standard recommendation for patients is to lose weight only. However this doesn’t work for everyone so if you are struggling to find a way to stop NASH, please read on.   Wha
A:
In 2010, some 4.7 million people aged 65 years or older lived with Alzheimer's disease in the US.   Alzheimer’s is a common brain disease that causes progressive brain cell death that happens over a course of time. It will also cause a shrink in brain size as the tissue has progressively fewer nerve cells and connections. Alzheimer’s is thought to be caused by Protein Plaques building up in the brain cells, these Plaques are found between the dying cel
A:
There are between 10 to 15 million patients in the U.S. with NASH, and among these patients, one-fifth to one-fourth are at risk for cirrhosis or chronic liver damage.   The major characteristic of NASH is fat in the liver, along with inflammation and damage. NASH can be severe and can lead to cirrhosis. The number of NASH cirrhosis patients is currently on the rise, and it is predicted (NAFLD & NASH) to be the number 1 cause of liver transplants by 2020. [1] Ther
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Have Questions?
Sumbit your question to us for profeessional answers!
Have
Questions?
Sumbit your question
to us for profeessional answers!
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Looking for help? Ask our customer support team!
Contact Us